Equities

Senti Biosciences Inc

SNTI:NAQ

Senti Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.12
  • Today's Change-0.08 / -3.64%
  • Shares traded18.43k
  • 1 Year change-68.82%
  • Beta2.7058
Data delayed at least 15 minutes, as of Nov 08 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Senti Biosciences Inc share price to rise to 6.00 in the next year from the last price of 2.12.
High183.0%6.00
Med183.0%6.00
Low183.0%6.00

Earnings history & estimates in USD

Earnings forecasts are not available for Senti Biosciences Inc. On Aug 13, 2024, Senti Biosciences Inc reported 2nd quarter 2024 losses of -- per share.
Average growth rate0.00%
Senti Biosciences Inc reported annual 2022 losses of -22.30 per share on Mar 22, 2023.
More ▼

Revenue history & estimates in USD

Revenue forecasts are not available for Senti Biosciences Inc.
Average growth rate-63.69%
Senti Biosciences Inc had revenues for the full year 2023 of 2.56m. This was 40.25% below the prior year's results.
Average growth rate-40.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.